In Re: Diet Drugs

Procedural entryThis page is a short order in In Re: Diet Drugs. Read the opinion of the Court — 282 F.3d 220
Court of Appeals for the Third Circuit·Decided January 25, 2005·No. 04-3591·Unpublished

Opinion

Opinions of the United 2005 Decisions States Court of Appeals for the Third Circuit

1-25-2005

In Re: Diet Drugs Precedential or Non-Precedential: Non-Precedential

Docket No. 04-3591

Follow this and additional works at: http://digitalcommons.law.villanova.edu/thirdcircuit_2005

Recommended Citation "In Re: Diet Drugs " (2005). 2005 Decisions. Paper 1552. http://digitalcommons.law.villanova.edu/thirdcircuit_2005/1552

This decision is brought to you for free and open access by the Opinions of the United States Court of Appeals for the Third Circuit at Villanova University School of Law Digital Repository. It has been accepted for inclusion in 2005 Decisions by an authorized administrator of Villanova University School of Law Digital Repository. For more information, please contact Benjamin.Carlson@law.villanova.edu. NOT PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

Nos. 04-3591, 04-3643 and 04-4096

IN RE: DIET DRUGS (PHENTERMINE/FENFLURAMINE/DEXFENFLURAMINE) PRODUCTS LIABILITY LITIGATION

Clara Clark and her agents, attorneys and derivative claimants; Linda Smart and her agents, attorneys and derivative claimants; Linda Eichmiller and her agents, attorneys and derivative claimants; Crystall Gatlin and her agents, attorneys and derivative claimants; Lonelle James and her agents, attorneys and derivative claimants; Doris Caldwell and her agents, attorneys and derivative claimants; Mitzi Wilson and her agents, attorneys and derivative claimants; Brenda Cook and Richard Cook and their agents, attorneys and derivative claimants,

Appellants at No. 04-3591

IN RE: CLARA CLARK, and her agents, attorneys and derivative claimants; LINDA SM ART, and her agents, attorneys and derivative claimants; LINDA EICHMILLER, and her agents, attorneys and derivative claimants; CRYSTALL GATLIN, and her agents, attorneys and derivative claimants; LONELLE JAM ES, and her agents, attorneys and derivative claimants; DORIS CALDW ELL, and her agents, attorneys and derivative claimants; MITZI WILSON, and her agents, attorneys and derivative claimants; BRENDA COOK and RICHARD COOK, and their agents, attorneys and derivative claimants,

Petitioners at No. 04-3643

1 IN RE: DIET DRUGS (PHENTERMINE/ FENFLURAMINE/DEXFENFLURAMINE) PRODUCTS LIABILITY LITIGATION

Clara Clark and her agents, attorneys and derivative claimants; Linda Smart and her agents, attorneys and derivative claimants; Linda Eichmiller and her agents, attorneys and derivative claimants; Crystall Gatlin and her agents, attorneys and derivative claimants; Lonelle James and her agents, attorneys and derivative claimants; Doris Caldwell and her agents, attorneys and derivative claimants; Mitzi Wilson and her agents, attorneys and derivative claimants; Brenda Cook and Richard Cook and their agents, attorneys and derivative claimants,

Appellants at No. 04-4096

____________

Appeal from the United States District Court for the Eastern District of Pennsylvania (D.C. No. MDL 1203) District Court Judge: Honorable Harvey Bartle, III ____________

Argued November 16, 2004 Before: ROTH, SMITH and WEIS, Circuit Judges. (Filed: January 25, 2005)

John G. Harkins, Jr. Steven A. Reed Harkins Cunningham 2005 Market Street 2800 One Commerce Square Philadelphia, PA 19103

2 George M. Fleming Sylvia Davidow Fleming & Associates 1330 Post Oak Boulevard, Suite 3030 Houston, TX 77056 Attorneys for Appellants/Petitioners

Fred S. Longer Arnold Levin Michael D. Fishbein Levin, Fishbein, Sedran & Berman 510 Walnut Street, Suite 500 Philadelphia, PA 19106 Attorneys for Plaintiffs’ Management Committee and Class Counsel

Robert D. Rosenbaum M. Sean Laane Arnold & Porter 555 12 th Street, N.W. Washington, D.C. 20004

Peter L. Zimroth Arnold & Porter 399 Park Avenue New York, NY 10022-4690

Paul B. Kerrigan Reed Smith 1650 Market Street 2500 One Liberty Place Philadelphia, PA 19103-7301 Attorneys for American Home Products Corporation ____________

OPINION ____________

3 WEIS, Circuit Judge.

The underlying issues here involve claims of personal injury caused by the

use of two appetite suppressant drugs produced and distributed by Wyeth. We provided a

lengthy summary of the facts in our opinions at 369 F.3d 293 (3d Cir. 2004) and 282 F.3d

220 (3d Cir. 2002). Consequently, we will limit our restatement of the background here.

I.

In the mid-1990s, data surfaced suggesting a link between use of the Wyeth

diet drugs and valvular heart disease (VHD) in humans. As a result, thousands of

lawsuits were filed against Wyeth in state and federal courts. The Judicial Panel for

Multidistrict Litigation transferred all the federal actions to the United States District

Court for the Eastern District of Pennsylvania.

In 1999, the parties reached a tentative settlement agreement for a

nationwide class. In exchange for Wyeth’s payment of $3.75 billion, the agreement

provided that settling class members would release Wyeth from all VHD claims. After

conducting a fairness hearing, the District Court entered a final order certifying the class

and approving the settlement on August 28, 2000. The terms of the settlement agreement

and the final order indicated that the District Court shall have continuing jurisdiction to

administer, interpret and enforce the settlement agreement.

Class members were entitled to opt out of the settlement agreement initially,

at an intermediate stage or at the "back-end." Those who decided to opt-out at the

4 intermediate stage were informed that the scope of their claims would be limited and

specifically they were precluded from “seeking” punitive, exemplary, or multiple

damages. The settlement agreement reads,

“[Intermediate opt-outs] may not seek punitive, exemplary, or any multiple damages against [Wyeth];.... [Intermediate opt- outs] may not use any previous verdicts or judgments against [Wyeth], or factual findings necessary to such verdicts or judgments, for purposes of establishing claims or facts in order to obtain a verdict or judgment. . . . Nor may [an intermediate opt-out] ... seek to introduce into evidence against [Wyeth], for any purpose, such a verdict, judgment or factual finding.”

In return for these limitations, Wyeth agreed not to assert any statute of

limitations, laches, or similar defenses against the intermediate opt-outs.

In state courts, most of the opt-out plaintiffs pleaded their claims in terms

that appeared to abide by the prohibition on seeking punitive damages. However, tactics

employed during litigation demonstrated that some plaintiffs were attempting to obtain

punitive-type damages through such means as inflated mental anguish recovery and by

presenting evidence of reprehensible conduct by Wyeth.

A. Initial Injunctions

In response to the attempted circumvention of the punitive damages bar, the

District Court issued PTO 2625 in plaintiff Clara Clark’s case as well as a similar pretrial

order, PTO 2828, applicable to other plaintiffs. In addition, the court issued PTO 3088

enjoining plaintiffs from making arguments related to punitive damages and malicious or

5 wanton conduct by Wyeth, as well as prohibiting them from introducing specific

categories of evidence and identified exhibits.

B. Initial Appeal

Plaintiffs appealed, contending that the injunctions did not comply with the

settlement agreement or notions of federalism. On May 25, 2004, we vacated PTO 2828

and remanded with instructions to the District Court to modify its pre-trial orders.1 In re

Diet Drugs, 369 F.3d at 317-19.

Free access — add to your briefcase to read the full text and ask questions with AI

In Re: Diet Drugs, (3d Cir. 2005).

In Re: Diet Drugs (In Re: Diet Drugs) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In Re Chambers Development Company, Inc.
148 F.3d 214 (Third Circuit, 1998)